Population genotyping only from July 1 st , 2010 Analysis are - - PowerPoint PPT Presentation



Population genotyping only from July 1st, 2010



Analysis are performed in 3 centers (Gent, Leuven, UCL Brussels)



Only for patients for whom MVC initiation is considered (fulfilling criteria for reimbursement)



Home‐made sequencing methods with ABI Big Dye terminator kits and ABI instrumentation (Gent‐UCL/Leuven – exchange of PCR failing samples).



Plasma RNA as standard, proviral DNA if VL <500 c/ml



Triplicate testing, both for RNA and DNA (evaluation period)



Manual proofreading (ABI software/ SmartGene IDNS & RECall)



Report: %FPR of triplicate tests with interpretation following ‘German recommendations’.

0,0 0,2 0,4 0,6 0,8 1,0 1,2 1,4 1,6 1,8 2,0 0,0 0,2 0,4 0,6 0,8 1,0 1,2 1,4 1,6 1,8 2,0

Log FPR ‐ proviral DNA Log FPR ‐ plasma viral RNA

Evaluation in collaboration with AM Wensing and R Paredes. Results are submitted as abstract to EHDRW 2010



101 samples (RNA and DNA) ‐ 265 results



Range of different VL



X4 prediction 10% FPR: 28% (+15% using 20% FPR) – single testing



RNA samples ‐ triplicate testing: discordant predictions of 8.6% (10% FPR) and 12.1% (20% FPR)



DNA samples: 9.3% and 18.6% respectively Single testing detected X4 in 24 (24%) of patients (10% FPR). Duplicate testing: 2 additional patients were scored X4 Triplicate testing: 2+1 additional patients were scored X4 Independent of viral load

VL CD4 RNA %FPR1 RNA %FPR2 RNA %FPR3 369 335000 93 6,9 6.9‐ 6.9‐ 625 >100000 60 8,7 8.7‐ 8.7‐ 415 9850 315 9,0 9.0‐ 9.0‐ 33 80600 21 7,8 6.0+ 6.6+ 9529 134000 287 5,0 2,9 6,0 941 100000 262 1,7 1.7+ 1.7+ 572 306000 223 7,8 7.8‐ 7.8‐ 8917 37600 538 9,9 23,6 9.9+ 9221 1318 414 31,6 33,7 33,7 9228 42800 205 17,1 17.1‐ 17.1‐ 9522 >100000 63 8,5 7.4+ 7.4+ 614 46600 908 33,9 33.9+ 33.9+ 621 153000 151 10,9 10.9‐ 10.9‐ 526 54300 163 12.5 5.3+ 7.8+ 891 1690 282 74,4 74.4 74.5 9322 374000 7 9,3 10.2+ 16.6+ 481 1300 260 19,5‐ 19,5‐ 19,5‐ 49 20700 161 6,9+ 5,8+ 15,7‐ 493 200000 104 3,7‐ 2,4+ 6,9‐ 595 162000 34 10,8‐ 3,9+ 3,9+ 514 13800 192 90,3 90,3 90,3 618 8730 381 3,7 3,7 3,7 635 >100000 232 32,7 28,8 32,7 669 8350 284 15,4 15,4 15,4

p p

24 selected samples. Concordant X4: 10; Concordant R5: 9; Discordant: 5

RNA %FPR1 RNA %FPR2 RNA %FPR3 9,9 23,6 9.9+ 8,5 7.4+ 7.4+ 12.5 5.3+ 7.8+ 9,3 10.2+ 16.6+ 6,9+ 5,8+ 15,7‐ 3,7‐ 2,4+ 6,9‐ 10,8‐ 3,9+ 3,9+ 3,7 3,7 3,7

Clinical outcome?